Is dulaglutide FDA-approved, and what does the research show?

What is dulaglutide?

Dulaglutide is a man-made protein that acts like GLP-1, a hormone the body makes itself ¹. GLP-1 stands for glucagon-like peptide-1; medicines that switch on its receptor are called GLP-1 receptor agonists, and dulaglutide is one ¹. The molecule has two identical chains, each a GLP-1-like peptide joined by a short linker to the Fc part of a modified human antibody, immunoglobulin G4 ¹.

The GLP-1 part matches 90 percent of the body's own GLP-1, with changes at the site where the enzyme DPP-4 would break it down ¹. It is made in cultured Chinese hamster ovary cells and weighs about 63 kilodaltons ¹. Eli Lilly sells it in the United States as Trulicity ².

Is dulaglutide FDA-approved?

Yes. Dulaglutide is approved by FDA as the prescription medicine Trulicity, with initial U.S. approval in 2014 ¹. FDA's Drugs@FDA record shows Eli Lilly's biologics license application, BLA 125469, approved on September 18, 2014, with marketing status "Prescription" ². FDA added the cardiovascular use by a supplement approved February 21, 2020, and the children's use by one approved November 17, 2022 ².

The label approves it "as an adjunct to diet and exercise to improve glycemic control" in adults and children aged 10 and older with type 2 diabetes ¹. It also approves it "to reduce the risk of major adverse cardiovascular events" in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors ¹.

Those are the label's two uses. It lists no indication for weight, and none for type 1 diabetes ¹. The Medication Guide adds that it is not known whether the medicine is safe and effective in children under 10 ¹. The route to it is a licensed clinician's prescription ¹. The label was last revised in March 2026 ¹.

See the FDA status of every peptide, updated weekly.

How does dulaglutide work?

Dulaglutide binds and activates the GLP-1 receptor, which sits on the surface of the insulin-making beta cells of the pancreas ¹. That raises a signal molecule inside the cell, cyclic AMP, and the cell releases insulin when glucose is high ¹. The label calls this glucose-dependent insulin release ¹. Dulaglutide also lowers glucagon secretion and slows the emptying of the stomach ¹.

In people with type 2 diabetes it lowers fasting glucose and the glucose rise after meals, and the label says the fall can be seen after a single dose ¹. Because the stomach empties more slowly, pills taken at the same time may be absorbed more slowly, most of all after the first dose ¹. This account of the mechanism is the label's, for an approved drug, from studies in people with type 2 diabetes ¹.

What does the research show?

The evidence for dulaglutide is at the top tier: FDA approval on randomized trials, and a large heart outcomes trial after it ¹, ³. The label's adult glucose trials tested it alone and added to metformin, a sulfonylurea, pioglitazone, SGLT2 inhibitors and insulin, and in people with moderate to severe kidney disease ¹. HbA1c, or hemoglobin A1c, is the blood measure these trials use for glucose control ¹.

Studied in people against placebo and exenatide: AWARD-1, published online in May 2014, randomized 976 adults with type 2 diabetes already taking metformin and pioglitazone ¹, ⁴. At 26 weeks, HbA1c fell by 1.3 and 1.5 points in the two dulaglutide arms of 280 and 279 people ¹, ⁴. It fell by 0.5 in the 141 on placebo and by 1.0 in the 276 on exenatide ¹, ⁴. Both dulaglutide arms beat placebo and exenatide on HbA1c ¹. An HbA1c below 7 percent was reached by 66 and 78 percent of them, against 43 on placebo and 52 on exenatide ¹.

Weight changed little: a gain of 0.2 kilograms and a loss of 1.3 in the dulaglutide arms, a gain of 1.2 on placebo and a loss of 1.1 on exenatide ¹. Hypoglycemia at 26 and 52 weeks was less common in the stronger dulaglutide arm than on exenatide, and no dulaglutide patient had severe hypoglycemia ⁴.

Studied in people for heart outcomes: REWIND, published online in June 2019, randomized 9,901 adults aged 50 or older with type 2 diabetes ³. Each had either a previous cardiovascular event or cardiovascular risk factors ³. It ran at 371 sites in 24 countries, double-blind, dulaglutide against placebo added to usual care, with a median follow-up of 5.4 years ³.

The primary outcome, a first non-fatal heart attack, non-fatal stroke or cardiovascular death, occurred in 594 of 4,949 (12.0 percent) on dulaglutide and 663 of 4,952 (13.4 percent) on placebo ³. That is a hazard ratio of 0.88, with a 95 percent confidence interval of 0.79 to 0.99 ³. Deaths from any cause were 10.8 percent against 12.0 percent, a difference that did not reach statistical significance ³. Most REWIND participants, 62.8 percent, had risk factors without established heart disease, and the median HbA1c at entry was 7.2 percent ¹. This is the trial the label cites for the cardiovascular indication ¹.

Studied in children: a 26-week, double-blind, placebo-controlled trial randomized 154 patients aged 10 to 17 with type 2 diabetes, with or without metformin or basal insulin ¹. In the two dulaglutide arms combined, 103 children, HbA1c fell by 0.8 points, while it rose by 0.6 in the 51 on placebo ¹. The difference was 1.4 points, with a 95 percent confidence interval of 0.8 to 1.9 ¹. Fifty-two percent of the children on dulaglutide reached an HbA1c below 7 percent, against 14 percent on placebo ¹.

Head to head with the newer drugs: SUSTAIN 7, an open-label trial published online in February 2018, compared semaglutide with dulaglutide ⁵. It randomized 1,201 adults with type 2 diabetes on metformin, about 300 to each of four arms, for 40 weeks ⁵. Semaglutide lowered HbA1c by 0.4 points more than dulaglutide at both of the matched dose levels, and body weight by 2.3 and 3.6 kilograms more ⁵. Gastrointestinal events were the most common adverse event, 33 to 48 percent, and the most common reason for stopping either drug ⁵. Six people died, one in each semaglutide arm and two in each dulaglutide arm, in a trial funded by Novo Nordisk ⁵.

SURPASS-CVOT, a double-blind trial published in December 2025, randomized 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide ⁶. Tirzepatide acts on the GLP-1 receptor and on a second incretin receptor, GIP ⁶. A cardiovascular death, heart attack or stroke occurred in 801 of 6,586 (12.2 percent) on tirzepatide and 862 of 6,579 (13.1 percent) on dulaglutide ⁶.

The hazard ratio was 0.92, with a 95.3 percent confidence interval of 0.83 to 1.01 ⁶. Tirzepatide met the test for being no worse than dulaglutide but not the test for being better, and had more gastrointestinal adverse events ⁶. The trial was funded by Eli Lilly, Trulicity's sponsor ⁶, ².

No published trial of dulaglutide for weight management, or in people without diabetes, was found among this page's sources as of November 9, 2026 ¹, ⁴, ³, ⁵, ⁶. Every trial above enrolled people with type 2 diabetes, and the weight changes reported are those seen in that population ¹, ⁴, ⁵.

What are the side effects?

Stomach and gut effects lead. In the label's pool of placebo-controlled adult trials, 1,670 patients took dulaglutide for a mean of 23.8 weeks ¹. Nausea was reported by 12.4 to 21.1 percent across the two dulaglutide arms, against 5.3 percent on placebo ¹. Diarrhea was reported by 8.9 to 12.6 percent against 6.7, and vomiting by 6.0 to 12.7 against 2.3 ¹.

Abdominal pain, decreased appetite, indigestion and fatigue were each reported by 4 to 9 percent, more than on placebo ¹. Gastrointestinal reactions of any kind occurred in 32 to 41 percent against 21 percent, and 1.3 to 3.5 percent stopped treatment because of them, against 0.2 percent on placebo ¹. In REWIND, 47.4 percent on dulaglutide reported a gastrointestinal adverse event over a median of 5.4 years, against 34.1 percent on placebo ³.

Hypoglycemia depends on what else is taken. Added to metformin alone, glucose below 54 mg/dL occurred in 0.3 to 0.7 percent at 26 weeks, against none on placebo ¹. With a sulfonylurea, 20 to 21 percent had such an episode over 78 weeks ¹. With mealtime insulin, 69 to 77 percent did over 52 weeks, and 2.7 to 3.4 percent had severe hypoglycemia ¹. Pancreatitis was confirmed in 5 patients on dulaglutide in the registration studies, 1.4 cases per 1,000 patient-years, against 1 case on non-incretin comparators ¹.

FDA's label carries a boxed warning at its head: dulaglutide "causes thyroid C-cell tumors in rats," and "it is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" ¹. The label contraindicates it in people with a personal or family history of MTC, in Multiple Endocrine Neoplasia syndrome type 2, and after a serious allergic reaction to dulaglutide ¹. Its warnings cover acute pancreatitis, hypoglycemia with insulin or a sulfonylurea, serious hypersensitivity reactions and acute kidney injury from dehydration ¹. They also cover severe gastrointestinal reactions, diabetic retinopathy complications, acute gallbladder disease, and pulmonary aspiration under general anesthesia ¹.

In REWIND, retinopathy complications occurred in 1.9 percent on dulaglutide against 1.5 percent on placebo, and in 8.5 against 6.2 percent among those with retinopathy at the start ¹. Post-marketing reports add anaphylaxis, angioedema, intestinal obstruction, acute kidney failure sometimes needing dialysis, and liver enzyme rises ¹. In children, injection-site reactions were more common than in adults ¹.

In sport

Dulaglutide is not named on WADA's 2026 Prohibited List, and GLP-1 receptor agonists are not a listed class ⁷. WADA, the World Anti-Doping Agency, lists insulins, insulin-mimetics and other metabolic modulators in section S4, but neither dulaglutide nor its class ⁷. Section S0 concerns substances with no current approval from any regulator; dulaglutide holds FDA approval, granted in 2014 ⁷, ¹.

What JumpstartMD offers

JumpstartMD does not prescribe dulaglutide. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 9, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.